Senti Biosciences, Inc. (SNTI)
- Previous Close
0.2900 - Open
0.2900 - Bid --
- Ask --
- Day's Range
0.2900 - 0.3085 - 52 Week Range
0.2700 - 1.2200 - Volume
40,687 - Avg. Volume
82,819 - Market Cap (intraday)
14.03M - Beta (5Y Monthly) 2.97
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8800 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
www.sentibio.comRecent News: SNTI
Performance Overview: SNTI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNTI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNTI
Valuation Measures
Market Cap
13.25M
Enterprise Value
14.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.51
Price/Book (mrq)
0.20
Enterprise Value/Revenue
7.58
Enterprise Value/EBITDA
-0.24
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.83%
Return on Equity (ttm)
-85.91%
Revenue (ttm)
2.56M
Net Income Avi to Common (ttm)
-83.41M
Diluted EPS (ttm)
-1.8800
Balance Sheet and Cash Flow
Total Cash (mrq)
35.97M
Total Debt/Equity (mrq)
56.29%
Levered Free Cash Flow (ttm)
-75.14M
Research Analysis: SNTI
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell